Skip to main content

Talk Bio

Search This Blog

Biogen and Denali halt Parkinson’s drug in non‑genetic Parkinson’s after mid‑stage failure

on May 22, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Biogen and Denali Therapeutics will discontinue development of their Parkinson’s disease drug BIIB122 in idiopathic (non-genetic) Parkinson’s disease after a mid‑stage trial failed to slow disease progression. The companies plan to keep studying the drug in patients with a specific genetic mutation linked to Parkinson’s.

Sources:

Closely watched experimental Parkinson's drug fails key clinical trial

Parkinson's drug development halted after midstage trial failure

Biogen, Denali begin late-stage testing of Parkinson's drug

Biogen cuts PhIII Parkinson's program over 'long timeline'

Biogen axes Denali-partnered Parkinson's drug after phase 2 flop

Denali Therapeutics Presents Positive Results from Phase 1 and ...

Biogen and Denali Therapeutics Provide Update on Phase ...

Biogen, Denali pull plug on Parkinson’s program after mid-stage flop

Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study

Biogen, Denali scrap Parkinson's drug after failure in mid-to-late ...

Biogen Terminates Phase III Parkinson's Study in Favor of Earlier ...

Biogen, Denali scrap Parkinson’s drug after failure in mid-to-late stage study

Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure - Biogen (NASDAQ:BIIB)

Beacon Biogen Denali idiopathic Parkinson 's disease LRRK2 gene Luma <eudicots> Mutation Parkinson 's disease

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Xaira Therapeutics Launches X-Cell: First AI Virtual Cell Model Testing Scaling Laws on Massive Perturbation Data

Xaira Therapeutics announced X-Cell on March 17, 2026, a 4.9-billion-parameter diffusion language model, the largest virtual cell model to date, trained on X-Atlas/Pisces, the largest genome-wide CRISPRi Perturb-seq dataset with 25.6 million perturbed single-cell transcriptomes across seven diverse contexts. 1 2 X-Cell predicts cell responses to genetic perturbations, outperforming existing models by up to five-fold on metrics like Pearson delta, and generalizes zero-shot to unseen biological contexts such as iPSC-derived melanocyte progenitors and primary human CD4+ T cells. 1 2 The model follows power-law scaling dynamics similar to large language models, using a novel diffusion architecture that iteratively refines predictions. 2 Xaira, founded in 2024 with over $1 billion funding, plans to expand X-Atlas to primary cells, organoids, and in vivo perturbations, focusing on inflammatory/immunological diseases and antibody therapeutics. 1 3 A subset of the Pisces dataset and X-...

Ultragenyx Resubmits BLA for UX111 Gene Therapy with New Long-Term Data for Sanfilippo Syndrome Type A

Ultragenyx resubmitted its Biologics License Application (BLA) to the FDA for UX111, an AAV9 gene therapy for Sanfilippo syndrome type A (MPS IIIA), including long-term clinical data on neurologic, biomarker, and safety improvements. 1 2 3 4 5 The resubmission addresses a Complete Response Letter from July 2025 related to manufacturing (CMC) observations and adds durable biomarker reductions, such as CSF heparan sulfate, with favorable safety profile. 2 4 5 FDA's six-month priority review has begun; PDUFA action date expected in Q3 2026. 2 4 5 If approved, UX111 would be the first therapy for this fatal pediatric neurodegenerative disorder. 1 3 4 5 New long-term data announced February 3, 2026, shows substantial biomarker improvements and functional benefits vs. natural history, consistent across age and severity. 2 Sources: 1. https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rare/ultragenyx-pharmaceutical/news/ultragenyx-bla-resubmission-puts-ux111-and-ra...

Powered by Blogger

X-Data LLC